Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Inhibition Of Autophagy By ACY-1215, a Selective HDAC6 Inhibitor Accelerates Carfilzomib-Induced Cell Death In Multiple Myeloma

Yuko Mishima, Loredana Santo, Diana D. Cirstea, Homare Eda, Neeharika Nemani, Shirin Arastu-Kapur, Ph.D, Christopher J. Kirk, Ph.D, Simon S Jones, PhD, Raje Noopur, MD

Blood (2013) 122 (21): 4431.

https://doi.org/10.1182/blood.V122.21.4431.4431

Published: 2013

Journal Articles

Blocking Protein Secretion and Degradation Is a Novel Treatment Strategy For Malignant Cells With High Protein Load

Eric Lowe, Rebecca Maglathlin, Alana Lerner, Ph.D, Jack Taunton, PhD, Christopher J. Kirk, Ph.D, Shirin Arastu-Kapur, Ph.D

Blood (2013) 122 (21): 4439.

https://doi.org/10.1182/blood.V122.21.4439.4439

Published: 2013

Journal Articles

Survival Pathways Stabilized By Proteasome Inhibition Reveal PIM2 As a Novel Target For Potentiating The Anti-Myeloma Activity Of Carfilzomib

Tracey Lin, B.S., Eric Lowe, B.S., Alana Lerner, Ph.D, Christopher J. Kirk, Ph.D, Shirin Arastu-Kapur, Ph.D

Blood (2013) 122 (21): 4440.

https://doi.org/10.1182/blood.V122.21.4440.4440

Published: 2013

Journal Articles

Carfilzomib, a Second-Generation Proteasome Inhibitor, In Combination With The Btk Inhibitor Ibrutinib As a Novel Therapeutic Regimen For Treating Double Hit DLBCL

Erin M Dominici, Elyse R Lopez, Muychi T Vang, Archito T. Tamayo, MS, Zhishuo Ou, MD, Alex Rollo, Liang Zhang, MD, PhD, Jack Wang, Lauren M Strickland, Michael Wang, MD, Richard J. Ford, MD, PhD, Lan V Pham, PhD, Christopher J. Kirk, Ph.D

Blood (2013) 122 (21): 1834.

https://doi.org/10.1182/blood.V122.21.1834.1834

Published: 2013

Journal Articles

Selective Inhibitor Of Nuclear Exports (SINE) KPT-330 In Combination With The Novel Proteasome Inhibitor Carfilzomib As a Novel Therapeutic Regimen For Treating Aggressive B-Cell Lymphomas

Elyse R Lopez, Erin M Dominici, Muychi T Vang, Archito T. Tamayo, MS, Zhishuo Ou, MD, Alex Rollo, Liang Zhang, MD, PhD, Jack Wang, Lauren M Strickland, Christopher J. Kirk, Ph.D, Michael Kauffman, MD, PhD, Sharon Shacham, PhD, MBA, Michael Wang, MD, Lan V Pham, PhD, Richard J. Ford, MD, PhD

Blood (2013) 122 (21): 5147.

https://doi.org/10.1182/blood.V122.21.5147.5147

Published: 2013

Journal Articles

Development Of Methods To Perform Next Generation Sequencing (NGS)-Based Genomics Studies On Multiple Myeloma Clinical Samples

Jonathan J Keats, PhD, Kevin A Kwei, PhD, Jeremiah D Degenhardt, Ph.D., Kristi Allen, BS, Christopher J. Kirk, Ph.D, Brian B Tuch, Ph.D.

Blood (2013) 122 (21): 5347.

https://doi.org/10.1182/blood.V122.21.5347.5347

Published: 2013

Journal Articles

Immunoglobulin Expression Is a Major Determinant Of Patient Sensitivity To Proteasome Inhibitors

Brian B Tuch, Ph.D., Andrea Loehr, Ph.D., Jeremiah D Degenhardt, Ph.D., Kevin A Kwei, PhD, Jonathan J Keats, PhD, Christopher J. Kirk, Ph.D

Blood (2013) 122 (21): 1903.

https://doi.org/10.1182/blood.V122.21.1903.1903

Published: 2013

Journal Articles

Inhibition Of The Immunoproteasome Subunit LMP7 Decreases Alloresponses In Both MHC-Mismatched and miHA-Disparate Murine Models Of Graft Versus Host Disease

Jennifer Matos, PhD, Zheng Yang, Eugenia Dziopa, Leah Dziopa, Christopher J. Kirk, Ph.D, Robert Korngold, PhD, Jenny Zilberberg, Ph.D.

Blood (2013) 122 (21): 4472.

https://doi.org/10.1182/blood.V122.21.4472.4472

Published: 2013

Journal Articles

The Novel Immunoproteasome Inhibitor PR-924: Anti-Leukemic Activity and Mechanisms Of Resistance

Denise Niewerth, MSc, Johan van Meerloo, MSc, Yehuda Assaraf, PhD, Gerrit Jansen, PhD, Tessa C Hendrickx, BSc, Christopher J. Kirk, Ph.D, Janet Anderl, MS, Sonja Zweegman, MD PhD, Jacqueline Cloos, PhD, Gertjan Kaspers, MD, PhD

Blood (2013) 122 (21): 3841.

https://doi.org/10.1182/blood.V122.21.3841.3841

Published: 2013

Journal Articles

Induction of Metabolic Impairment In Prolonged Early G1 Arrest Induced by CDK4/CDK6 Inhibition Sensitizes Myeloma Cells for Proteasome Inhibitor Killing During Subsequent S Phase Synchronization

Maurizio Di Liberto, Ph.D., Xiangao Huang, Ph.D., Jamieson Bretz, Ph.D., Scott A Ely, M.D., Rediet Zewdu, B.S., David Jayabalan, B.S.M.S, Suzhen Chen, B.S., Christopher J Kirk, Ph.D., Sophia Randolph, M.D., Ph.D., Ruben Niesvizky, M.D., Ph.D., Selina Chen-Kiang, Ph.D.

Blood (2010) 116 (21): 2989.

https://doi.org/10.1182/blood.V116.21.2989.2989

Published: 2010

Journal Articles

Bortezomib-Resistant Cell Lines Have Increased Proteasome Levels but Remain Sensitive to Carfilzomib.

Erika Suzuki, Susan Demo, PhD, Shirin Arastu-Kapur, PhD, Christopher J Kirk, Ph.D, Mark K Bennett, PhD

Blood (2009) 114 (22): 2852.

https://doi.org/10.1182/blood.V114.22.2852.2852

Published: 2009

Journal Articles

Neurodegeneration Induced by Bortezomib Exposure in Vitro Occurs Via Proteasome Independent Mechanisms.

Shirin Arastu-Kapur, PhD, Andrew J. Ball, PhD, Janet L. Anderl, Mark K Bennett, PhD, Christopher J Kirk, Ph.D

Blood (2009) 114 (22): 2859.

https://doi.org/10.1182/blood.V114.22.2859.2859

Published: 2009

Journal Articles

Dose Intensive Administration of PR-047, a Novel Orally Bioavailable Inhibitor of the 20S Proteasome, Is Well Tolerated in Experimental Animals.

Tony Muchamuel, Shirin Kapur, PhD, Christopher J Kirk, Ph.D, Jing Jiang, M.D., Susan Lee, Mark K Bennett, PhD, Evan Lewis, Jinfu Yang, Mouhannad Jumaa, Eileen Ring, Pasit Phiasivongsa, Han-Jie Zhou, PhD, Zhengping Wang

Blood (2009) 114 (22): 4910.

https://doi.org/10.1182/blood.V114.22.4910.4910

Published: 2009

Journal Articles

Preclinical Pharmacology and in Vitro Characterization of PR-047, An Oral Inhibitor of the 20S Proteasome

Tony Muchamuel, Monette Aujay, Mark K Bennett, PhD, Maya Dajee, Susan Demo, PhD, Christopher J Kirk, Ph.D, Ying Fang, Jing Jiang, M.D., Evan Lewis, Yan Lu, Guy Laidig, Francesco Parlati, PhD, Jamie Shields, Congcong m Sun, Jinfu Yang, Han-Jie Zhou, PhD

Blood (2008) 112 (11): 3671.

https://doi.org/10.1182/blood.V112.11.3671.3671

Published: 2008

Journal Articles

Immunoproteasome-Selective Keto-Epoxide Inhibitors: Potential Therapeutic Agents for the Treatment of Hematological Disorders.

Francesco Parlati, PhD, Monette A. Aujay, B.S., Susan D. Demo, Ph.D., Eileen D. Goldstein, B.S., Jing Jiang, B.S., Christopher J. Kirk, Ph.D., Guy J. Laidig, Ph.D., Yan Lu, M.S., Tony Muchamuel, M.S., Kevin D. Shenk, M.S., Catherine Sylvain, Ph.D., Congcong M. Sun, M.S., Tina M. Woo, B.S., Han-Jie Zhou, Ph.D., Mark K. Bennett, Ph.D.

Blood (2006) 108 (11): 4392.

https://doi.org/10.1182/blood.V108.11.4392.4392

Published: 2006

NARROW

Inhibition Of Autophagy By ACY-1215, a Selective HDAC6 Inhibitor Accelerates Carfilzomib-Induced Cell Death In Multiple Myeloma

Blocking Protein Secretion and Degradation Is a Novel Treatment Strategy For Malignant Cells With High Protein Load

Survival Pathways Stabilized By Proteasome Inhibition Reveal PIM2 As a Novel Target For Potentiating The Anti-Myeloma Activity Of Carfilzomib

Carfilzomib, a Second-Generation Proteasome Inhibitor, In Combination With The Btk Inhibitor Ibrutinib As a Novel Therapeutic Regimen For Treating Double Hit DLBCL

Selective Inhibitor Of Nuclear Exports (SINE) KPT-330 In Combination With The Novel Proteasome Inhibitor Carfilzomib As a Novel Therapeutic Regimen For Treating Aggressive B-Cell Lymphomas

Development Of Methods To Perform Next Generation Sequencing (NGS)-Based Genomics Studies On Multiple Myeloma Clinical Samples

Immunoglobulin Expression Is a Major Determinant Of Patient Sensitivity To Proteasome Inhibitors

Inhibition Of The Immunoproteasome Subunit LMP7 Decreases Alloresponses In Both MHC-Mismatched and miHA-Disparate Murine Models Of Graft Versus Host Disease

The Novel Immunoproteasome Inhibitor PR-924: Anti-Leukemic Activity and Mechanisms Of Resistance

Induction of Metabolic Impairment In Prolonged Early G1 Arrest Induced by CDK4/CDK6 Inhibition Sensitizes Myeloma Cells for Proteasome Inhibitor Killing During Subsequent S Phase Synchronization

Bortezomib-Resistant Cell Lines Have Increased Proteasome Levels but Remain Sensitive to Carfilzomib.

Neurodegeneration Induced by Bortezomib Exposure in Vitro Occurs Via Proteasome Independent Mechanisms.

Dose Intensive Administration of PR-047, a Novel Orally Bioavailable Inhibitor of the 20S Proteasome, Is Well Tolerated in Experimental Animals.

Preclinical Pharmacology and in Vitro Characterization of PR-047, An Oral Inhibitor of the 20S Proteasome

Immunoproteasome-Selective Keto-Epoxide Inhibitors: Potential Therapeutic Agents for the Treatment of Hematological Disorders.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only